Literature DB >> 17226739

Alzheimer's disease.

Roy Yaari1, Jody Corey-Bloom.   

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Currently, 4.5 million individuals in the United States are estimated to have AD, and that number is projected to increase to at least 14 million by the year 2050. AD is a major cause of disability and mortality, and its impact on health care costs, including direct and indirect medical and social service costs, is estimated to be greater than $100 billion per year. AD typically presents with an insidious decline in memory that progresses to affect language, visuospatial perception, calculations, and executive functioning. Behavioral and psychiatric symptoms are also frequent in AD. Diagnosis is determined clinically, as there is currently no laboratory test to confirm AD in life. The neuropathologic hallmarks of AD are neuritic plaques and neurofibrillary tangles. Currently available medical therapies have demonstrated modest benefits but likely do not alter disease progression. Caregivers play a large role in managing the patient and should be encouraged to seek out adult day care centers, home health services, respite care, and additional social support.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17226739     DOI: 10.1055/s-2006-956753

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  30 in total

1.  Predicting cognitive decline and conversion to Alzheimer's disease in older adults using the NAB List Learning test.

Authors:  Brandon E Gavett; Al Ozonoff; Vlada Doktor; Joseph Palmisano; Anil K Nair; Robert C Green; Angela L Jefferson; Robert A Stern
Journal:  J Int Neuropsychol Soc       Date:  2010-04-07       Impact factor: 2.892

2.  Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain.

Authors:  Ganna Lyubartseva; Jennifer L Smith; William R Markesbery; Mark A Lovell
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

Review 3.  A potential role for zinc alterations in the pathogenesis of Alzheimer's disease.

Authors:  Ganna Lyubartseva; Mark A Lovell
Journal:  Biofactors       Date:  2012-03-23       Impact factor: 6.113

Review 4.  Current and emerging drug treatment options for Alzheimer's disease: a systematic review.

Authors:  Nathan Herrmann; Sarah A Chau; Ida Kircanski; Krista L Lanctôt
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

5.  Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.

Authors:  Marwan N Sabbagh; Adam Fleisher; Kewei Chen; Joseph Rogers; Camryn Berk; Eric Reiman; Michael Pontecorvo; Mark Mintun; Daniel Skovronsky; Sandra A Jacobson; Lucia I Sue; Carolyn Liebsack; Albert S Charney; Lauren Cole; Christine Belden; Thomas G Beach
Journal:  Arch Neurol       Date:  2011-11

6.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

7.  Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease.

Authors:  Claudio Liguori; Agostino Chiaravalloti; Marzia Nuccetelli; Francesca Izzi; Giuseppe Sancesario; Andrea Cimini; Sergio Bernardini; Orazio Schillaci; Nicola Biagio Mercuri; Placidi Fabio
Journal:  J Neurol       Date:  2017-09-12       Impact factor: 4.849

8.  Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  J Nanoneurosci       Date:  2009-06-01

Review 9.  Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies.

Authors:  Olga Zolochevska; Giulio Taglialatela
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 10.  Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.

Authors:  Marwan N Sabbagh; Holly A Shill
Journal:  Curr Opin Investig Drugs       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.